Vasospasm News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Vasospasm. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Vasospasm Today - Breaking & Trending Today
Ocular migraine consists of brief periods of visual loss in one eye, which is accompanied or preceded by a headache. Flashing and zigzag lights are symptoms. ....
Results published in the Journal of Neurosurgery show that clazosentan significantly reduced the combined incidence of vasospasm-related morbidity and all-cause mortality post-aSAH with no unexpected safety ....
Comaneci temporarily expands blood vessels-recognized as novel device for life-threatening disease Rapid Medical, a leading developer of advanced neurovascular devices, today announced FDA breakthrough ....
email article Moderate fish consumption was associated with lower long-term cardiovascular disease (CVD) risk in high-risk individuals and those with existing vascular disease but not in the general population, according to a large pooled analysis. In the largely CVD-naïve PURE study cohort, individuals who ate 350 g (or four servings of fish) a week were not better off than peers with little or no fish intake in terms of major CVD events (HR 0.95, 95% CI 0.86-1.04) or total mortality (HR 0.96, 95% CI 0.88-1.05) over a median 9.1 years of follow-up. By contrast, moderate fish consumption at 175 g (two servings) per week was associated with reduced risk of major CVD (HR 0.84, 95% CI 0.73-0.96) and total mortality (HR 0.82, 95% CI 0.74-0.91) among the smaller ONTARGET, TRANSCEND, and ORIGIN cohorts of people with vascular disease or diabetes. Risk did not sink further with greater fish intake in this group. ....
email article An FDA advisory committee turned thumbs down on Becton Dickinson s Lutonix 014 drug-coated balloon (DCB) for peripheral artery disease (PAD) during a virtual meeting on Wednesday. Circulatory System Devices Panel members voted 14-3 (with one abstention) that the benefits of the investigational angioplasty catheter do not outweigh its risks as a treatment for patients with critical limb ischemia (CLI) who have obstructive de novo or non-stented restenotic lesions in below-the-knee (BTK) arteries. Committee members were largely unconvinced that the Lutonix DCB was supported by adequate efficacy data. In the pivotal Lutonix BTK IDE trial, the device showed a 10.5% absolute advantage in the primary efficacy endpoint (combined primary patency and limb salvage) at 6 months that was not significant under Bayesian analysis. Such improvement, if any, vanished by 12 months, and the endpoint started to favor the regular percutaneous transluminal angioplast ....